Evidence map›Paper›PMID 38461480›Full record

ArticleInfectious diseases and therapy2024

Longitudinal Molecular and Serological Evidence of SARS-CoV-2 Infections and Vaccination Status: Community-Based Surveillance Study (CONTACT).

Olga Sánchez-Soliño, Ryan D Kilpatrick, Christopher Johnson, Yixin Fang, Yizhou Ye, Negar Niki Alami, Katarzyna Zarish, Whitney S Krueger, Nancy Dreyer, Gregory C Gray

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious diseases and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04611230 (EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04611230 completednot on this map

EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois: CONTACT

TypeobservationalSponsorAbbVieRan2020 to 2021Enrolled1,007ConditionsSevere Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2)
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Olga Sánchez-SoliñoAbbVie Inc., 26525 Riverwoods Blvd., Mettawa, North Chicago, IL, 60045, USA. olga.sanchez@abbvie.com.
Ryan D KilpatrickAbbVie Inc., North Chicago, IL, USA.
Christopher JohnsonAbbVie Inc., North Chicago, IL, USA.
Yixin FangAbbVie Inc., North Chicago, IL, USA.
Yizhou YeAbbVie Inc., North Chicago, IL, USA.
Negar Niki AlamiAbbVie Inc., North Chicago, IL, USA.
Katarzyna ZarishAbbVie Inc., North Chicago, IL, USA.
Whitney S KruegerAbbVie Inc., North Chicago, IL, USA.
Nancy DreyerIQVIA Real World Solutions, Cambridge, MA, USA.
Gregory C GrayDivision of Infectious Diseases, School of Medicine, University of Texas Medical Branch, Galveston, TX, USA.
AbbVie (United States) · USIQ Solutions · USThe University of Texas Medical Branch at Galveston · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis prospective, longitudinal, community-based study, EpidemiologiCal POpulatioN STudy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Lake CounTy, Illinois (CONTACT), investigated coronavirus disease 2019 (COVID-19) immunity, occupational risks related to SARS-CoV-2 exposure, and long-term immunoglobulin G (IgG) seroconversion kinetics.

methodsAt baseline and follow up (3, 6, and 9 months), non-hospitalized adult participants provided nasal and blood serum specimens for molecular [reverse transcription polymerase chain reaction (RT-PCR)] and serological (IgG) testing (4 November 2020-30 October 2021).

resultsAt baseline, 6.4% (65/1008) had evidence of current/prior SARS-CoV-2 infection. At 3, 6, and 9 months, positive PCR tests were obtained from 0.4% (3/781), 0.4% (3/733), and 0% (0/673) of participants, respectively. Positive IgG occurred at baseline and 3, 6, and 9 months in 4.5% (45/1008), 6.0% (48/799), 5.4% (39/733), and 2.8% (19/673) of participants, respectively. Of participants positive for IgG at baseline, 28 had a negative IgG test at a follow-up visit; of those 28,  21 had their first negative IgG test within 6 months. Participants were more likely to retain positive IgG if they were 18-29 years of age, were male, or had medium-high/high-risk occupations. A high vaccination rate (70% received ≥ 1 dose by 9 months) was observed. Influence of occupational status or characteristics on transmission and IgG, and COVID-19 vaccination trends, are shown.

conclusionsThis study expands on prior studies assessing COVID-19 immunity and IgG seroconversion by including both RT-PCR and serologic testing and longitudinal follow-up of study participants. We observed decreased infection rates over the 9 month follow-up period as well as a decline in IgG persistency after 6 months. The findings from this community-based study regarding vaccinate rates, infection rates by PCR, and IgG persistency over time can help improve our understanding of COVID-19 immunity, occupational risks related to SARS-CoV-2 exposure, and the kinetics of long-term IgG seroconversion, which is important to help guide local and national mitigation strategies. CLINICAL

trial registrationNCT04611230.

Indexed as

Community-based researchCOVID-19EpidemiologySARS-CoV-2

Identifiers

PMID38461480
PMCPMC11058157
OpenAlexW4392632390

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.